Hidetoshi Hoshiya has been appointed as a new board director as of December 1, 2020.
Dr. Hoshiya has more than 15 years of experience in the field of regenerative medicine, cell and gene therapy, having served for more than four years as the manager for Asia and Oceania at the Cell and Gene Therapy Catapult, a regenerative medicine industrialization organization in the UK.
Utilizing Dr. Hoshiya’s experience and knowledge in the industrialization of cell therapy, we will greatly accelerate the clinical application of high production cell culture technology.
Graduated from Tottori University in 2009. PhD in Regenerative Medicine, is a Fellow of the Royal Society of Arts and a member of the Royal Society of Biology.
D. in Regenerative Medicine at Tottori University, San Raffaele Scientific Institute (Italy), University College London and Queen Mary University (UK). In November 2019, he became an independent consultant for startups, non-profit organizations, and major pharmaceutical companies. In December 2020, he was appointed to the board of CellFiber. He has more than 15 years of experience in the fields of regenerative medicine, cell and gene therapy.
Comment from Hidetoshi Hoshiya
I believe that CellFiber’s technology has the potential to become the golden standard for mass production of regenerative medical products, including cell and gene therapies. We will do our best to provide highly effective and safe regenerative medical products to patients quickly and inexpensively.